Valuation: Karyopharm Therapeutics Inc.

Market Cap 8L 7L 7L 6L 11.44L 7.46Cr 11.89L 81.31L 32.14L 4.03Cr 29.95L 29.32L 13Cr P/E 2026 *
-0.01x
P/E 2027 * -0.02x
Enterprise Value 8L 7L 7L 6L 11.44L 7.46Cr 11.89L 81.31L 32.14L 4.03Cr 29.95L 29.32L 13Cr EV / Sales 2026 *
0.01x
EV / Sales 2027 * -
Free-Float
91.84%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Karyopharm Therapeutics Inc.

1 day-0.57%
1 week+100.00%
Current month-94.71%
1 month-89.88%
3 months-98.19%
6 months-99.51%
Current year-99.52%
1 week 0.01
Extreme 0.0102
0.04
1 month 0.01
Extreme 0.008
0.99
Current year 0.01
Extreme 0.008
10.99
1 year 0.01
Extreme 0.008
10.99
3 years 0.01
Extreme 0.008
29.25
5 years 0.01
Extreme 0.008
220.95
10 years 0.01
Extreme 0.008
444.15
Manager TitleAgeSince
Chief Executive Officer 58 03/05/2021
Director of Finance/CFO 55 03/01/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member 63 01/01/2013
Director/Board Member 61 01/04/2013
Director/Board Member 78 03/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26 Sell

Controller/Auditor

-4,788 0.0211%
01/10/26 Sell

Controller/Auditor

-378 0.0017%
01/09/26 Sell

Controller/Auditor

-19 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+100.00%-99.44%-99.70% 8L
-2.32%-3.79%+34.24%+131.38% 1,26100Cr
-2.15%-2.75%+36.35%+81.91% 67TCr
-2.33%-3.04%+22.29%+106.79% 52TCr
-0.69%+0.40%+40.46%+69.78% 39TCr
-3.90%-6.39%+42.88%+34.18% 35TCr
-1.35%-2.23%+24.30%+56.34% 30TCr
-1.13%-1.71%+0.40%+33.00% 28TCr
-3.07%-5.17%+29.04%+67.28% 25TCr
-0.75%-0.44%+32.87%+122.34% 21TCr
Average -1.84%-3.18%+16.34%+60.33% 42TCr
Weighted average by Cap. -1.97%-0.55%+31.06%+90.68%

Financials

2026 *2027 *
Net sales 13Cr 12Cr 11Cr 10Cr 19Cr 1.26TCr 20Cr 136.86Cr 54Cr 677.82Cr 50Cr 49Cr 2.14TCr 16Cr 15Cr 13Cr 12Cr 23Cr 1.49TCr 24Cr 162.84Cr 64Cr 806.48Cr 60Cr 59Cr 2.55TCr
Net income -16Cr -14Cr -13Cr -12Cr -22Cr -1.46TCr -23Cr -158.87Cr -63Cr -786.84Cr -59Cr -57Cr -2.48TCr -12Cr -11Cr -9.81Cr -8.86Cr -17Cr -1.09TCr -17Cr -118.52Cr -47Cr -587Cr -44Cr -43Cr -1.85TCr
Net Debt - -
Projected Income Statement - Annual - Karyopharm Therapeutics Inc.
Logo Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Employees
228
Date Price Change Volume
19/26/19 $0.0350 -0.57% 10,61,943
17/26/17 $0.0352 +23.08% 23,61,167
16/26/16 $0.0286 +12.60% 13,73,579
13/26/13 $0.0254 -0.39% 14,99,539
12/26/12 $0.0255 +45.71% 27,11,602
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Karyopharm Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0352USD
Average target price
7.000USD
Spread / Average Target
+19,786.36%
  1. Stock Market
  2. Stocks
  3. KPTIQ Stock